Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.
To explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical, biological, and cytogenetic characteristics (myeloid neoplasias only) as well as outcome. Furthermore, we will register the clinical, biological, and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given.
Study Type
OBSERVATIONAL
Enrollment
642
Kjeld Schmiegelow
Copenhagen, Denmark
Pattern of SMN subtypes
Pattern of the main groups of SMN and their clinical charactiristics
Time frame: At 20 years from diagnosis
Overall survival by subtype
Overall survival by the main SMN subtypes (myeloid malignancies, brain tumors, lymphomas, sarcomas, carcinomas, others)
Time frame: At 10 years from diagnosis of SMN
Risk factors for development of SMN
Identification of risk factors linked to the interval to SMN, the subtype of SMN, and the survival after. These risk factors are clinical characteristics of ALL or the anti-ALL therapy administered
Time frame: At 20 years from ALL diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.